John Thompson, MD
Ophthalmology · Baltimore, MDNPI 1073584439
Payments from drug & device makers
Across 359 payments — averaging $5129.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.7M
- Ocular Therapeutix, Inc.$87K
- AstraZeneca$44K
- Astrazeneca AB$17K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$777
- plus $3K from 14 others
Across 2 payments — averaging $725.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 212 | $1,688,994 |
| Ocular Therapeutix, Inc. | 13 | $86,655 |
| AstraZeneca | 3 | $43,822 |
| Astrazeneca AB | 1 | $17,205 |
| Regeneron Healthcare Solutions, Inc. | 30 | $1,039 |
| Genentech USA, Inc. | 24 | $777 |
| Halozyme Inc | 4 | $688 |
| AbbVie(2 entities) | 24 | $627 |
| Notal Vision, Inc. | 1 | $456 |
| Apellis Pharmaceuticals, Inc. | 12 | $329 |
| Stryker | 6 | $282 |
| Novartis | 9 | $179 |
| Coherus Oncology, Inc. | 4 | $132 |
| Biogen | 4 | $82 |
| Astellas Pharma US Inc | 2 | $67 |
| Sandoz | 2 | $65 |
| Bausch & Lomb Americas Inc. | 3 | $53 |
| Harrow Eye, LLC | 2 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$1,841,549 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Baltimore
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$1.1M
- Earl CravenBaltimore$315K
- Akosua NtiBaltimore$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.